The Motley Fool

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...
The Motley Fool

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. Investors looking for stocks that can make dramatic gains often turn ...
Business Insider

Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...
Nasdaq

Is Recursion Pharmaceuticals Stock a Buy?

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of ...
Nasdaq

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...